(NASDAQ: CRVO) Cervomed's forecast annual revenue growth rate of 208.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Cervomed's revenue in 2025 is $9,737,974.On average, 3 Wall Street analysts forecast CRVO's revenue for 2025 to be $24,367,613, with the lowest CRVO revenue forecast at $17,405,438, and the highest CRVO revenue forecast at $35,681,148. On average, 1 Wall Street analysts forecast CRVO's revenue for 2030 to be $939,893,652, with the lowest CRVO revenue forecast at $939,893,652, and the highest CRVO revenue forecast at $939,893,652.
In 2031, CRVO is forecast to generate $2,636,923,857 in revenue, with the lowest revenue forecast at $2,636,923,857 and the highest revenue forecast at $2,636,923,857.